Ten-Year Results of Edwards Lifesciences’ Resilia Tissue
Edwards Lifesciences announced 10-year results from the COMMENCE aortic trial, highlighting the long-term durability and sustained performance of its RESILIA tissue. Presented at the American Association for Thoracic Surgery Annual Meeting, the findings emphasize the need for durable valve solutions as evidence supports earlier treatment in valve disease.
CHICAGO–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv